NIH and Lilly to create public medicines resource
March 14, 2012 -- The National Institutes of Health (NIH) and the pharmaceutical firm Eli Lilly and Company have announced that they will produce a publicly available resource to profile the effects of thousands of approved and investigational medicines. NIH and Lilly are creating the resource in an effort to make drug development pipelines more productive and efficient. According to the NIH, improved knowledge of these medicines could help researchers to better predict treatment outcomes, improve drug development, and lead to more specific and effective approaches.
Through the collaboration, the NIH's National Center for Advancing Translational Sciences (NCATS) and Lilly Research Laboratories have agreed that NCATS’ Pharmaceutical Collection of 3,800 approved and investigational medicines will be screened using Lilly’s state-of-the-art Phenotypic Drug Discovery (PD2) panel.
"This innovative collaboration with Lilly is exactly the type of partnership that NCATS is eager to foster with many other groups from industry, government, and academia," said NCATS Acting Director Thomas R. Insel. "Working together, we can make drug development pipelines more productive. The key is precompetitive collaboration to benefit all partners, ensuring broad access to the results."
- To read more about the resource, click here.
- To read more about NCATS in the GHTC’s 2012 policy report, click here.